MRC1 and cervical cancer: Consistent with our findings, Bonneville et al analyzed whole exome sequencing data from The Cancer Genome Atlas (TCGA) cervical cancer cohort (n=305) and identified MSI in 2.6% of the tumors.30 We did not detect any significant differences in survival between patients with MMR-deficient and MMR-proficient tumors, which is in line with previous reports.27 30